These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22386518)

  • 1. Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.
    McKee SJ; Young VL; Clow F; Hayman CM; Baird MA; Hermans IF; Young SL; Ward VK
    J Control Release; 2012 May; 159(3):338-45. PubMed ID: 22386518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response.
    Peacey M; Wilson S; Perret R; Ronchese F; Ward VK; Young V; Young SL; Baird MA
    Vaccine; 2008 Oct; 26(42):5334-7. PubMed ID: 18706958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo.
    Li K; Peers-Adams A; Win SJ; Scullion S; Wilson M; Young VL; Jennings P; Ward VK; Baird MA; Young SL
    J Immunother; 2013 Jan; 36(1):11-9. PubMed ID: 23211625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.
    Peacey M; Wilson S; Baird MA; Ward VK
    Biotechnol Bioeng; 2007 Dec; 98(5):968-77. PubMed ID: 17546687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcutaneous vaccination with virus-like particles.
    Young SL; Wilson M; Wilson S; Beagley KW; Ward V; Baird MA
    Vaccine; 2006 Jun; 24(26):5406-12. PubMed ID: 16621190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant.
    Crisci E; Almanza H; Mena I; Córdoba L; Gómez-Casado E; Castón JR; Fraile L; Bárcena J; Montoya M
    Virology; 2009 May; 387(2):303-12. PubMed ID: 19327809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
    Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
    Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.
    Boczkowski D; Lee J; Pruitt S; Nair S
    Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
    Li B; VanRoey MJ; Jooss K
    Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
    Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
    Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
    Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
    Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
    Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
    J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.